The Use Of MicroRNA As Novel Therapeutic Targets For Reducing Retinal Inflammation And Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$349,076.00
Summary
Age-Related Macular Degeneration (AMD) is the most common cause of blindness in Australia. We aim to investigate a new class of potential therapeutics, microRNA which are involved in the regulation of many biological processes, including inflammation. A greater understanding of these miRNA will enable discovery of novel therapeutic targets for inflammatory diseases like AMD, and will have further reaching applications in other inflammatory disease such as Alzheimer’s and Parkinson’s.